TELA Bio, Inc. — Form 8-K Summary
Business context and reporting period
On September 28, 2026, TELA Bio, Inc. entered into a Limited Consent to its November 13, 2025 Credit Agreement and Guaranty with Perceptive Credit Holdings V, LP, as administrative and collateral agent, and the required lenders. The report was signed on September 29, 2026.
Financial position and key metrics
The filing states that lenders had made term loans and other financial accommodations available under the credit agreement. It provides no amounts for revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material change
The agent and consenting lenders agreed that the credit agreement’s minimum Revenue covenant will not be tested for the fiscal quarters ending on or about September 30, 2026 and December 31, 2026. The filing does not disclose the covenant threshold or the company’s actual or projected revenue.
Outlook, risks and contingencies
This is a limited covenant consent, not a disclosure of financial results or a broader amendment to the credit agreement. The filing does not explain the reason for the consent or provide further management commentary or guidance. The company said the full consent would be filed as an exhibit to its Form 10-Q for the quarter ended September 30, 2026.
Investor verification points
- Review the full Limited Consent when filed, including its scope and any conditions.
- Check the September 30, 2026 Form 10-Q for revenue, liquidity, debt terms, and any discussion of covenant compliance or financial outlook.
- Determine whether any further lender consents, waivers, or amendments are disclosed.